Bret Kenwell

Bret Kenwell is a freelance writer for TheStreet. He studied finance at Central Michigan University and seeks out companies that have the ability to generate above-average growth for many years. Ultimately, the goal is for those companies to become dividend paying titans, cementing their spot in one's portfolio with an incredibly low cost basis. Those picks and Bret's blog can be found at FutureBlueChips.com

 

Twitter: @BretKenwell

Recent Articles By The Author

Snap Stock Could Dive 27% on Fears Over App Redesign and High Valuation

Snap Stock Could Dive 27% on Fears Over App Redesign and High Valuation

Snap stock is falling Tuesday after a downgrade to sell from hold by Citi analyst Mark May.

Kraft Heinz Stock Grinds to New Lows on Poor Earnings

Kraft Heinz Stock Grinds to New Lows on Poor Earnings

Kraft Heinz does not have the products that younger shoppers want. The end result is a poor quarterly report, as the company missed earnings and revenue expectations.

Campbell Soup Is 'Behind the Eight Ball', Jim Cramer Says

Campbell Soup Is 'Behind the Eight Ball', Jim Cramer Says

Campbell Soup beat on earnings per share and revenue expectations, but the company is struggling with its key segments and customers.

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

3 Reasons Pfizer May Want to Buy Bristol-Myers Squibb

Could Pfizer really buy Bristol-Myers Squibb? Despite the latter's $112 billion market cap, Citi analyst Andrew Baum lays out the case for why it makes sense.

Bristol-Myers 'Is Back' and Could Soar Another 14%

Bristol-Myers 'Is Back' and Could Soar Another 14%

Could Bristol-Myers Squibb stock really jump another 14% after rallying 12% so far in 2018? According to Morgan Stanley, the answer is 'yes.'